Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNeurocrine Biosciences, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 9 | $1.02 | $1.22 | $1.11 |
| Q2 2026 | 9 | $1.15 | $1.76 | $1.43 |
| Q3 2026 | 3 | $1.56 | $1.85 | $1.72 |
| Q4 2026 | 7 | $1.56 | $1.85 | $1.72 |
| Q1 2027 | 3 | $1.76 | $2.08 | $1.94 |
| Q2 2027 | 3 | $2.07 | $2.45 | $2.28 |
| Q3 2027 | 4 | $2.21 | $2.62 | $2.44 |
| Q4 2027 | 3 | $2.25 | $2.66 | $2.48 |
Neurocrine Biosciences, Inc. Earnings Date And Information
Neurocrine Biosciences, Inc. last posted its earnings results on Wednesday, February 11th, 2026. The company reported $1.88 earnings per share for the quarter, missing analysts' consensus estimates of $2.25 by $0.37. The company had revenue of 805.50 M for the quarter and had revenue of 2.86 B for the year. Neurocrine Biosciences, Inc. has generated $5 earnings per share over the last year ($4.67 diluted earnings per share) and currently has a price-to-earnings ratio of 27.05. Neurocrine Biosciences, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Neurocrine Biosciences, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/11/2026 | Q4 2025 | $2.25 | $1.54 | -0.71 | $790.50 M | $805.50 M |
| 10/28/2025 | Q3 2025 | $1.58 | $2.11 | 0.53 | $746.85 M | $794.90 M |
| 07/30/2025 | Q2 2025 | $0.98 | $1.09 | 0.11 | $653.88 M | $687.50 M |
| 05/05/2025 | Q1 2025 | $0.54 | $0.08 | -0.46 | $559.63 M | $572.60 M |
| 02/10/2025 | Q4 2024 | N/A | $1.03 | N/A | $629.46 M | $627.70 M |
| 10/30/2024 | Q3 2024 | $1.51 | $1.28 | -0.23 | $600.64 M | $622.10 M |
| 08/01/2024 | Q2 2024 | $1.05 | $0.64 | -0.41 | $545.98 M | $590.20 M |
| 05/01/2024 | Q1 2024 | $1.01 | $0.43 | -0.58 | $512.40 M | $515.30 M |
| 02/09/2024 | Q4 2023 | N/A | $1.50 | N/A | N/A | $515.20 M |
| 10/31/2023 | Q3 2023 | $0.97 | $0.85 | -0.12 | N/A | $498.80 M |
| 08/01/2023 | Q2 2023 | $0.78 | $0.98 | 0.2 | N/A | $452.70 M |
| 05/03/2023 | Q1 2023 | $0.26 | -$0.79 | -1.05 | N/A | $420.40 M |
| 02/09/2023 | Q4 2022 | N/A | $0.92 | N/A | N/A | $412.00 M |
| 11/01/2022 | Q3 2022 | $0.79 | $0.72 | -0.07 | N/A | $387.90 M |
| 08/04/2022 | Q2 2022 | $0.56 | -$0.18 | -0.74 | N/A | $378.20 M |
| 05/04/2022 | Q1 2022 | $0.35 | $0.15 | -0.2 | N/A | $310.60 M |
| 02/11/2022 | Q4 2021 | $0.61 | -$0.08 | -0.69 | N/A | $312.00 M |
| 11/01/2021 | Q3 2021 | $0.51 | $0.24 | -0.27 | N/A | $296.00 M |
| 08/03/2021 | Q2 2021 | $0.48 | $0.45 | -0.03 | N/A | $288.90 M |
| 05/05/2021 | Q1 2021 | $0.51 | $0.34 | -0.17 | N/A | $236.60 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Neurocrine Biosciences, Inc. Earnings: FAQ's
The conference call for Neurocrine Biosciences, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Neurocrine Biosciences, Inc.'s latest earnings report can be read online.
Neurocrine Biosciences, Inc. (:NBIX) has a recorded annual revenue of $2.86 B.
Neurocrine Biosciences, Inc. (:NBIX) has a recorded net income of $478.60 M.Neurocrine Biosciences, Inc. has generated $4.81 earnings per share over the last four quarters.
Neurocrine Biosciences, Inc. (:NBIX) has a price-to-earnings ratio of 27.05 and price/earnings-to-growth ratio is 2.29.